GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  American Journal of Physiology. Endocrinology and Metabolism

• Publication date

  2013-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/ajpendo.00600.2012PMID 23571712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Wnt Signaling Pathway Effector TCF7L2 Controls Gut and Brain Proglucagon Gene Expression and Glucose Homeostasis

  2013cited by this paper
• Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism

  2012cited by this paper
• In Vivo Role of Focal Adhesion Kinase in Regulating Pancreatic β-Cell Mass and Function Through Insulin Signaling, Actin Dynamics, and Granule Trafficking

  2012cited by this paper
• The role of the Wnt signaling pathway in incretin hormone production and function

  2012cited by this paper
• A Rac1/PAK1 cascade controls β-catenin activation in colon cancer cells

  2012cited by this paper
• GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity.

  2012cited by this paper
• Insulin detemir enhances proglucagon gene expression in the intestinal L cells via stimulating β-catenin and CREB activities.

  2012cited by this paper
• Curcumin Prevents High Fat Diet Induced Insulin Resistance and Obesity via Attenuating Lipogenesis in Liver and Inflammatory Pathway in Adipocytes

  2012cited by this paper
• The Wnt signaling pathway effector TCF7L2 is upregulated by insulin and represses hepatic gluconeogenesis.

  2012cited by this paper
• Cardiovascular biology of the incretin system.

  2012cited by this paper
• GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.

  2011cited by this paper
• GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes.

  2011cited by this paper
• GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes

  2011cited by this paper
• Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic beta-cells.

  2010cited by this paper
• Effect of Treatment of Sprague Dawley Rats with AVE7688, Enalapril, or Candoxatril on Diet-Induced Obesity

  2010cited by this paper
• Wingless-type MMTV integration site family (WNT) signalling in pancreatic beta cells—more complex than expected

  2010cited by this paper
• Featured Insulin-like actions of glucagon-like peptide-1 : a dual receptor hypothesis

  2010cited by this paper
• Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

  2010cited by this paper
• Wnt and incretin connections.

  2010cited by this paper
• WNT/β-catenin increases the production of incretins by entero-endocrine cells

  2009cited by this paper
• Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

  2008cited by this paper
• Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin.

  2008cited by this paper
• Glucagon-like Peptide-1 Activation of TCF7L2-dependent Wnt Signaling Enhances Pancreatic Beta Cell Proliferation*

  2008cited by this paper
• Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells.

  2008cited by this paper
• Mechanisms underlying proglucagon gene expression.

  2008cited by this paper
• SiRNA‐Mediated β‐catenin Knockdown in Human Hepatoma Cells Results in Their Decreased Growth and Survival

  2007cited by this paper
• siRNA-Mediated β-Catenin Knockdown in Human Hepatoma Cells Results in Decreased Growth and Survival*

  2007cited by this paper
• Phosphorylation of β-Catenin by Cyclic AMP-dependent Protein Kinase*

  2006cited by this paper
• Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005

  2006cited by this paper
• Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase.

  2006cited by this paper
• The biology of incretin hormones.

  2006cited by this paper
• Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination.

  2005cited by this paper
• Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.

  2005cited by this paper
• TCF-4 Mediates Cell Type-specific Regulation of Proglucagon Gene Expression by β-Catenin and Glycogen Synthase Kinase-3β*

  2005cited by this paper
• Phosphorylation of β-Catenin by Cyclic AMP-Dependent Protein Kinase Stabilizes β-Catenin through Inhibition of Its Ubiquitination

  2005cited by this paper
• Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig

  2005cited by this paper
• TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta.

  2005cited by this paper
• Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs.

  2004cited by this paper
• Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy

  2004cited by this paper
• The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism.

  2004cited by this paper
• Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.

  2003cited by this paper
• Transcriptional Activation of the Proglucagon Gene by Lithium and β-Catenin in Intestinal Endocrine L Cells*

  2003cited by this paper
• The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells.

  2003cited by this paper
• Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo.

  2003cited by this paper
• Members of the Kv1 and Kv2 voltage-dependent K(+) channel families regulate insulin secretion.

  2001cited by this paper
• The glucagon-like peptides.

  1999cited by this paper
• Insulin Stimulates cAMP-response Element Binding Protein Activity in HepG2 and 3T3-L1 Cell Lines*

  1998cited by this paper
• Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor.

  1996cited by this paper
• Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides.

  1995cited by this paper
• The cAMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase A.

  1991cited by this paper

• Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications

  2025cites this paper
• Food regulation of incretin axis: Molecular mechanisms and clinical outlook in diabetes

  2025cites this paper
• Current understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists

  2025cites this paper
• Melatonin and GABA monotherapies are as efficacious as combination therapy in managing T1D and T2D: In-vivo studies on experimental diabetic models

  2025cites this paper
• Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification

  2024cites this paper
• Hepatic function of glucagon-like peptide-1 and its based diabetes drugs

  2024cites this paper
• Gabaergic System in the Regulation of the Functioning of Pancreas Beta-Cells in Normal Physiological Conditions and in Diabetes

  2023cites this paper
• Short‐term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice

  2023cites this paper
• Liraglutide attenuates palmitate-induced apoptosis via PKA/β-catenin/Bcl-2/Bax pathway in MC3T3-E1 cells

  2023cites this paper
• Novel GLP-1(28-36) amide-derived hybrid peptide A3 with weight loss and hypoglycemic activities.

  2023cites this paper
• Possible mechanisms and molecular signaling of incretins against the development of type 2 diabetes mellitus.

  2022cites this paper
• Phosphoproteomic Analysis Reveals Downstream PKA Effectors of AKAP Cypher/ZASP in the Pathogenesis of Dilated Cardiomyopathy

  2021cites this paper
• Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.

  2021cites this paper
• The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury

  2021cites this paper
• Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α.

  2020influential citation
• Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System

  2020cites this paper
• Display of quintuple glucagon‐like peptide 1 (28–36) nonapeptide on Bacillus subtilis spore for oral administration in the treatment of type 2 diabetes

  2020cites this paper
• Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt/β-catenin signaling.

  2020cites this paper
• The developmental Wnt signaling pathway effector β-catenin/TCF mediates hepatic functions of the sex hormone estradiol in regulating lipid metabolism

  2019cites this paper
• Experimental study on the effect of Tibetan Medicine Triphala on the Proliferation and apoptosis of Pancreatic Islet β cells through incretin/cAMP signaling Pathway.

  2019cites this paper
• Moderate preventative effect with intraperitoneal liraglutide injection in high-fat diet induced C57BL/6J obese mouse model

  2019cites this paper
• Combined effect of GABA and glucagon‐like peptide‐1 receptor agonist on cytokine‐induced apoptosis in pancreatic β‐cell line and isolated human islets

  2019cites this paper
• Acute effect of an amino acid mixture in the rat glycemic profile

  2019cites this paper
• GABAergic regulation of pancreatic islet cells: Physiology and antidiabetic effects

  2019cites this paper
• Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1

  2018cites this paper
• The LIM homeodomain protein ISL1 mediates the function of TCF7L2 in pancreatic beta cells.

  2018cites this paper
• Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.

  2018cites this paper
• Novel GLP‐1R/GIPR co‐agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury

  2017cites this paper
• Pancreatic-derived factor impaired glucagon-like Peptide-1 production from GLUTag enterendorine L-cell line and intestines.

  2017cites this paper
• Is There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus?

  2017cites this paper
• GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products

  2017cites this paper
• Inhibition of Y1 receptor signaling improves islet transplant outcome

  2017cites this paper
• PGLP‐1, a novel long‐acting dual‐function GLP‐1 analog, ameliorates streptozotocin‐induced hyperglycemia and inhibits body weight loss

  2017influential citation
• Combined Oral Administration of GABA and DPP-4 Inhibitor Prevents Beta Cell Damage and Promotes Beta Cell Regeneration in Mice

  2017cites this paper
• Current concepts regarding developmental mechanisms in diabetic retinopathy in Taiwan

  2016cites this paper
• Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives.

  2016influential citation
• Glucagon Like Peptide-1 Promotes Adipocyte Differentiation via the Wnt4 Mediated Sequestering of Beta-Catenin

  2016cites this paper
• Transcriptional regulation of the miR-212/miR-132 cluster in insulin-secreting β-cells by cAMP-regulated transcriptional co-activator 1 and salt-inducible kinases.

  2016cites this paper
• Molecular basis of cAMP signaling in pancreatic β cells

  2015cites this paper
• Liver-Specific Expression of Dominant-Negative Transcription Factor 7-Like 2 Causes Progressive Impairment in Glucose Homeostasis

  2015cites this paper
• GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice

  2015influential citation
• The expression of dominant negative TCF7L2 in pancreatic beta cells during the embryonic stage causes impaired glucose homeostasis

  2015cites this paper
• Liraglutide Activates AMPK Signaling and Partially Restores Normal Circadian Rhythm and Insulin Secretion in Pancreatic Islets in Diabetic Mice.

  2015cites this paper
• FSP-1 Impairs the Function of Endothelium Leading to Failure of Arteriovenous Grafts in Diabetic Mice.

  2015cites this paper
• Novel Pentapeptide GLP‐1 (32–36) Amide Inhibits β‐Cell Apoptosis In Vitro and Improves Glucose Disposal in Streptozotocin‐Induced Diabetic Mice

  2015cites this paper
• GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?

  2014cites this paper
• Microenvironmental stimuli for proliferation of functional islet β-cells

  2014cites this paper
• The Role of Transcription Factor 7-Like 2 in Hepatic Glucose Metabolism

  2014cites this paper
• GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?

  2014influential citation
• GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?

  2014influential citation
• GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?

  2014influential citation
• Molecular Basis of cAMP Signaling in Pancreatic b Cells 20

  2014cites this paper
• Regulation of glucose homeostasis by GLP-1.

  2014cites this paper
• GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells.

  2014cites this paper
• GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs.

  2014cites this paper
• GLP-1(28-36)amide, a Long Ignored Peptide Revisited

  2014cites this paper
• Cardiovascular effects of incretins in diabetes.

  2013cites this paper
• GLP-1-derived nonapeptide GLP-1(28-36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice.

  2013cites this paper
• SUPPLEMENTAL DATA Cardioprotective GLP-1 metabolite prevents ischemic injury by inhibiting mitochondrial trifunctional protein-α

  year unknowninfluential citation